Rebemadli has been shown to enhance apoptosis mediated by MRPL21 deficiency in hepatoma cell lines Hep3B and HCCLM3 by inhibiting P53 activity.61 This evidence concerns the gene MRPL21 and hepatocellular carcinoma.